PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide ...

Christopher Mutz; Senior Vice President, Head of Rare Diseases; ANI Pharmaceuticals Inc Stephen Carey; Chief Financial Officer, Senior Vice President; ANI Pharmaceuticals Inc Good morning everyone.

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript February 28, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.63, expectations were $1.41.

Fintel reports that on March 14, 2025, Jefferies initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Buy recommendation. Analyst Price Forecast Suggests 29.28% Upside As of March 4, 2025, ...

ANI Pharmaceuticals is introducing nitazoxanide tablets, 500 mg, which is the generic of Alinia. The medication is used to treat diarrhea caused by certain parasites. "The market launch of ...

ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the ...

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals ANIP over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

ANI Pharmaceuticals Stock Down 0.1 % Shares of ANIP opened at $64.26 on Friday. The firm has a market cap of $1.40 billion, a P/E ratio of -116.84 and a beta of 0.63. ANI Pharmaceuticals, Inc. has ...

(MENAFN- GlobeNewsWire - Nasdaq) PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide ...